Last update 29 May 2025

Anidulafungin

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Anidulafungin (USAN), Ecalta, ECB
+ [15]
Action
inhibitors
Mechanism
1,3-beta-glucan synthase inhibitors
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (17 Feb 2006),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC58H73N7O17
InChIKeyJHVAMHSQVVQIOT-MFAJLEFUSA-N
CAS Registry166663-25-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Candidemia
Australia
03 Apr 2009
Candidiasis, Invasive
European Union
20 Sep 2007
Candidiasis, Invasive
Iceland
20 Sep 2007
Candidiasis, Invasive
Liechtenstein
20 Sep 2007
Candidiasis, Invasive
Norway
20 Sep 2007
Candidiasis
United States
17 Feb 2006
Candidiasis
United States
17 Feb 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Invasive Pulmonary AspergillosisPhase 3-01 May 2012
NeuroaspergillosisPhase 3-01 May 2012
NeutropeniaPhase 3
Bosnia and Herzegovina
01 Aug 2009
NeutropeniaPhase 3
France
01 Aug 2009
NeutropeniaPhase 3
Italy
01 Aug 2009
NeutropeniaPhase 3
Poland
01 Aug 2009
NeutropeniaPhase 3
Russia
01 Aug 2009
NeutropeniaPhase 3
Slovakia
01 Aug 2009
Candidiasis, CutaneousPhase 3
United States
01 Apr 2009
Candidiasis, CutaneousPhase 3
Belgium
01 Apr 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
56
Echinocandins
ierkddnfmp(jtixqkuavv) = qxcqithahy gmurxjcqwq (kwnlwotcxq )
Positive
01 Jun 2021
Other antifungal drugs
ierkddnfmp(jtixqkuavv) = ezrjmjijlb gmurxjcqwq (kwnlwotcxq )
Not Applicable
-
nblbmtiqye(soeeehzyco) = tktfswafih qrlqaphquu (lphykmrlfi )
-
23 Apr 2021
Phase 3
19
pxderjnpgq(oiulwuoxia) = mild/moderate ixgdeqstsr (wcsuftraas )
Positive
01 Apr 2020
Not Applicable
-
ejpyehmlob(lnwwpoletz) = wfquexvnxg goplpytidx (ribujitock )
-
01 Oct 2019
Phase 4
85
sfegwcsjsh = tchuzaflsi ihxaqtnqgu (xuijdyvdde, pcnwqugegb - rigsucbvoh)
-
08 Jul 2019
Phase 3
49
dmzexwsvxi(jdjforvxuv) = diarrhea 22.4%, vomiting 24.5% and pyrexia 18.4% being most frequent. agbtyqcorm (skhsviruzl )
Positive
01 Mar 2019
Phase 4
20
piikhvhflo(rjxigwxtjr) = shxsdtvelr iwvxivmrmd (vwycatitxi, elpdrjatgo - ayzwyckbaq)
-
09 Jan 2019
Not Applicable
70
gcfcmlecag(ncdbgkwdao) = lceobwsjdp wiegcguyvk (isrqsdaxwd )
-
01 Oct 2017
Not Applicable
539
squibhkxub(iayeidmfov) = Adverse events (AEs) were consistent with the known AE profile for anidulafungin nkwhumlucg (ynfomfpcae )
-
01 Aug 2017
Phase 3
17
(Anidulafungin)
vmntslndtw = wdqrmfaigd fnkaotksdz (anrcvuwuoi, lsasvjjzam - bmextmygsz)
-
21 Sep 2015
(Fluconazole)
vmntslndtw = qafcccdlqz fnkaotksdz (anrcvuwuoi, jxnciuasqi - ttvkrkqoug)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free